Amgen Beats Decade-Old Investor Suit Over Off-Label Scheme
A California judge Tuesday dismissed a decade-old action claiming Amgen Inc.'s board caused more than $1 billion in damages by overseeing an off-label drug marketing scheme, saying the shareholder failed to...To view the full article, register now.
Already a subscriber? Click here to view full article